Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267472 | 0.98 | MAPT (0.67) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL15997261 | 0.90 | MAPT (0.65) | CNR2MAPTTP53ALDH1A1GAA | |
| SCHEMBL16420885 | 0.88 | CXCR2 (0.56) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL3917243 | 0.87 | MAPT (0.79) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL3916162 | 0.86 | MAPT (0.80) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL16420905 | 0.84 | HSD17B10 (0.64) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL3039770 | 0.84 | CNR2 (0.69) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL8290510 | 0.84 | MAPT (0.77) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL7892222 | 0.84 | MAPT (0.84) | CNR2MAPTTP53HPGDHSD17B10 | |
| SCHEMBL265899 | 0.83 | MAPT (0.61) | CNR2MAPTTP53HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772490-B1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2772490-A1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | SLC34A2, SLC10A2, ALPI | CNR2 849/4885MAPT 1901/4885TP53 3228/4885 |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | CNR2 1412/4885MAPT 4195/4885TP53 2556/4885 |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | CNR2 924/4885MAPT 4648/4885TP53 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.